---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-129712"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:12:51.324283+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Acrivon provides pipeline and AP3 update, reports cash runway into Q4 2024

## Summary
- Hosted virtual investor event on May 1, 2023 with updated corporate presentation.
- Disclosed cash and marketable securities as of March 31, 2023 (amount not specified in filing).
- Confirmed cash runway extends into at least Q4 2024.
- Presentation highlights progress on AP3 precision proteomics platform and pipeline.

## SEC filing metadata
- accession: 0001193125-23-129712
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523129712/0001193125-23-129712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523129712/d283996d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-129712
- JSON: https://secwatch.observer/filing/0001193125-23-129712.json
- Plain text: https://secwatch.observer/filing/0001193125-23-129712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.